These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 10070963

  • 1. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans.
    Fuse E, Tanii H, Takai K, Asanome K, Kurata N, Kobayashi H, Kuwabara T, Kobayashi S, Sugiyama Y.
    Cancer Res; 1999 Mar 01; 59(5):1054-60. PubMed ID: 10070963
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
    Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S.
    Cancer Res; 1998 Aug 01; 58(15):3248-53. PubMed ID: 9699650
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Review of UCN-01 development: a lesson in the importance of clinical pharmacology.
    Fuse E, Kuwabara T, Sparreboom A, Sausville EA, Figg WD.
    J Clin Pharmacol; 2005 Apr 01; 45(4):394-403. PubMed ID: 15778420
    [Abstract] [Full Text] [Related]

  • 9. Controlled release of a protein kinase inhibitor UCN-01 from liposomes influenced by the particle size.
    Yamauchi M, Kusano H, Saito E, Abe M, Tsutsumi K, Uosaki Y, Nakakura M, Kato Y, Aoki N.
    Int J Pharm; 2008 Mar 03; 351(1-2):250-8. PubMed ID: 17904317
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics.
    Huang Z, Ung T.
    Curr Drug Metab; 2013 Feb 03; 14(2):226-38. PubMed ID: 23092311
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: role of alpha-1-acid glycoprotein.
    Yasuhara M, Fujiwara J, Kitade S, Katayama H, Okumura K, Hori R.
    J Pharmacol Exp Ther; 1985 Nov 03; 235(2):513-20. PubMed ID: 2997437
    [Abstract] [Full Text] [Related]

  • 16. Identification of alpha-1-acid glycoprotein (orosomucoid) as a major vanilloid binding protein in serum.
    Szallasi A, Lewin NE, Blumberg PM.
    J Pharmacol Exp Ther; 1992 Sep 03; 262(3):883-8. PubMed ID: 1527730
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.
    Frapolli R, Zucchetti M, Sessa C, Marsoni S, Viganò L, Locatelli A, Rulli E, Compagnoni A, Bello E, Pisano C, Carminati P, D'Incalci M.
    Eur J Cancer; 2010 Feb 03; 46(3):505-16. PubMed ID: 20007015
    [Abstract] [Full Text] [Related]

  • 20. Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir.
    Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, Liang Z, Halifax K, Lindup WE, Back DJ.
    Drug Metab Dispos; 2001 Mar 03; 29(3):299-303. PubMed ID: 11181499
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.